News | April 14, 2025
Novartis to invest $23 billion on expansion of manufacturing and R&D facilities in US
Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities
Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities
This approval marks a significant milestone in OneSource’s ongoing commitment to quality and regulatory compliance
Shilpa’s product has been approved as a generic version to the innovator - Chantix Tablets, 0.5 mg and 1 mg, of PF Prism C.V. (PF Prism)
Raichur site is the group’s largest API facility and part of a wider network of seven sites
Asahi Kasei Life Science covers a broad range of bioprocess products and services
Findings likely to generate hypotheses about potential new uses of drugs
Awards highlight Avantor's commitment to the Biopharma industry
Being a premium partner for pharmaceutical companies by contributing to safety and productivity of pharmaceutical manufacture
Lonza’s new simplified and streamlined operating model is designed to support its One Lonza vision and strategy
Dupixent (dupilumab) approved as the first-ever biologic medicine in Japan for patients with Chronic Obstructive Pulmonary Disease (COPD)
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
